Vigabatrin: Phase IIb started

Catalyst began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate CPP-109 in about 200 cocaine-dependent patients. Patients will receive twice-daily 1.5 g oral CPP-109 or placebo for...